Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.